Merck-U02-Substudy 02B - Clinical Trial
What is the Purpose of this Study?
We are doing this study to find out if two experimental drugs called MK-7684 and MK-1308 are safe and effective treatments for melanoma. We will combine these drugs with other cancer drugs in this study.
Melanoma
Who Can Participate in the Study?
Adults ages 18+ who:
- Are diagnosed with stage III or IV melanoma
For more information about who can be in this study, please contact the study team at ivy.belskie@duke.edu.
What is Involved?
The study is divided into two periods: a screening period and a study dosing period.
If you choose to join this study, during the screening period you will:
- Have physical exams
- Have blood draws
- Have a tumor biopsy
- Have heart scans (ECG and echocardiogram)
- Have images taken (CT or MRI)
If you are found to be eligible, you will continue on to the study dosing period. During this period, you will:
- Be randomly assigned to 1 of 4 groups
-- Group 1 will get pembrolizumab and MK-7684
-- Group 2 will get pembrolizumab alone
-- Group 3 will get MK-1308A (pembrolizumab + MK-1308)
-- Group 4 will get MK-1308A and lenvatinib
Pembrolizumab, MK-7684, and MK-1308 are all given as intravenous (IV) infusions. Lenvatinib is a capsule you take by mouth.
Study Details
